1. Home
  2. PSMT vs ERAS Comparison

PSMT vs ERAS Comparison

Compare PSMT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PriceSmart Inc.

PSMT

PriceSmart Inc.

HOLD

Current Price

$174.13

Market Cap

5.2B

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$12.10

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSMT
ERAS
Founded
1994
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
5.5B
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
PSMT
ERAS
Price
$174.13
$12.10
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$14.25
AVG Volume (30 Days)
179.0K
4.5M
Earning Date
04-08-2026
05-08-2026
Dividend Yield
0.91%
N/A
EPS Growth
5.47
36.23
EPS
2.91
N/A
Revenue
$4,066,093,000.00
N/A
Revenue This Year
$12.29
N/A
Revenue Next Year
$10.70
N/A
P/E Ratio
$59.47
N/A
Revenue Growth
12.33
N/A
52 Week Low
$99.98
$1.24
52 Week High
$174.93
$24.28

Technical Indicators

Market Signals
Indicator
PSMT
ERAS
Relative Strength Index (RSI) 66.53 47.02
Support Level $153.14 $9.80
Resistance Level N/A $16.14
Average True Range (ATR) 4.96 0.98
MACD 0.55 0.36
Stochastic Oscillator 75.96 41.68

Price Performance

Historical Comparison
PSMT
ERAS

About PSMT PriceSmart Inc.

Pricesmart Inc is principally engaged in operating U.S.-style membership shopping warehouse clubs that offer consumer goods at low prices. The company is headquartered in San Diego, California, United States, and operates stores in the Caribbean, Costa Rica, Panama, and other regions. The company's revenue consists of net warehouse club sales from merchandise sales, membership income from annual membership fees, export sales, and other income. Its operations consist of four reportable segments; Central America, the Caribbean, Colombia, and the United States. A majority of the company's revenue is derived from Central America.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: